Articles by: Craig Ardmore

PTC Therapeutics Upgraded to Outperform by RBC

PTC Therapeutics Upgraded to Outperform by RBC

June 20, 2018 at 10:07 am

PTC Therapeutics (PTCT) received an investment-rating upgrade Monday to outperform from sector perform from RBC Capital Markets following the biopharmaceutical company’s Saturday release of interim clinical data from the first part of a study of its risdiplam treatment in infants with Type 1 Spinal Muscular Atrophy, a genetic neuromuscular disorder. RBC also raised its price target on PTC’s shares toRead More

Overnight Fixed Income Wrap: 10-Year Bund Yields Up 3.3 bps at 0.492%

June 7, 2018 at 4:07 am

Ten-year Bund yields rose 3.3 basis points to 0.492% in opening trade, with the 0.5% mark coming into sight as a hawkish turn at the European Central Bank continued to put pressure on global bond markets. Ten-year Treasury yields were up 0.6 bp at 2.977%, while 10-year Japanese government bonds eased 0.1 bp to 0.038%. ECB chief economist Peter PraetRead More

Anika Therapeutics Due Off Halt at 435 PM ET

Anika Therapeutics Due Off Halt at 435 PM ET

May 2, 2018 at 4:28 pm

Anika Therapeutics (ANIK) is due off a trading halt at 435 PM ET. The company said Q1 sales slipped to $21.3 million from the year-ago period’s $23.4 million and missesd the CapIQ mean for $24.3 milllion. It swung to a net loss per share of $0.46 from a $0.37 profit last year and missed forecasts for a quarter gain. ItRead More

Square Q1 Results Top Expectations; Shares Fall After Hours

Square Q1 Results Top Expectations; Shares Fall After Hours

May 2, 2018 at 4:26 pm

Square (SQ) reported adjusted net income of $0.06 per share in Q1, a penny better than the consensus on Capital IQ and compared with the year earlier gain of $0.05 a share. The payments company’s stock was down about 5% in early after-hours trading. Adjusted revenue surged 51% to $307 million, ahead of the analysts’ views for $293.1 million. SquareRead More

Aptose Shares Surge Following Encouraging Pre-Clinical Data on CG’806

Aptose Shares Surge Following Encouraging Pre-Clinical Data on CG’806

April 18, 2018 at 1:55 pm

Aptose Biosciences (APTO) shares jumped in Monday trading after the Canadian-based clinical-stage biotechnology company said preclinical data demonstrated the robust cell killing ability of CG’806, a pan-FLT3/pan-BTK inhibitor, in multiple types of AML and B-cell malignancies. Data further demonstrated CG’806 targets multiple pathways and overcomes drug resistance seen with other inhibitors, the company said in a statement. “As a pan-FLT3/pan-BTKRead More

Boeing Faces Risks in China-US Trade Dispute

April 5, 2018 at 1:12 pm

Escalation of a trade dispute between China and the US is bringing uncertainty with Boeing (BA) facing substantial risks given that the Asian nation’s tariffs announced this week include levies on the airplane maker’s 737 next generation craft, Canaccord Genuity said. China’s “very quick response” to the Trump administration includes a 25% tariff on aircraft weighing between about 33,000 andRead More

Facebook in Relief Rally as CEO Zuckerberg & Deutsche Bank Soothe Nerves

Facebook in Relief Rally as CEO Zuckerberg & Deutsche Bank Soothe Nerves

April 5, 2018 at 1:03 pm

Shares of Facebook (FB) climbed more than 2% intraday day after Deutsche Bank analyst Lloyd Walmsley is reported to have reiterated a Buy rating and $200 price target on the company, saying he is “cautiously optimistic a bottom is in,” according to media reports. That comes as CEO Mark Zuckerberg told reporters, according to CNBC, that he had not seenRead More